Pacific Biosciences Of California, Inc. · NASDAQ:PACB
Pacific Biosciences Of California — Q1 2026 Earnings Presentation
16 slides from Pacific Biosciences Of California's earnings presentation, May 7, 2026
Slide 1: Q1 2026 Earnings Presentation
Q1 2026 Earnings Presentation May 7, 2026 1
Slide 2: Safe harbor and non-GAAP disclosures
Safe harbor and non-GAAP disclosures Statement regarding use of non‐GAAP financial measures PacBio reports non‐GAAP results for basic net income and loss per share, net income, net loss, gross margins, gross profit (loss), and operating expenses in addition to, and not as a substitute for, or becaus
Slide 3: Q1 2026 Summary
Q1 2026 Summary $37.2M Flat Y/Y $9.7M (12%) Y/Y Instrument Revenue Total Revenue 15 Revio Systems 27 Vega Systems ~50% to new customers ~85% to new customers $21.8M 9% Y/Y Consumable Revenue Cumulative Revio and Vega Shipments • Record quarter 331 346 310 • ~$229,000 annualized Revio pull- 297 throu
Slide 4: SPRQ-Nx is designed to deliver high-quality HiFi at a highly competitive price point
SPRQ-Nx is designed to deliver high-quality HiFi at a highly competitive price point Designed to deliver among the most complete view of the genome SPRQ-Nx for less than $300 per genome at scale Full launch Multi-use SMRT cells Intended to reduce the cost of sequencing for customers planned later an
Slide 5: DNAstack collaboration is expected to create the largest, most diverse federated HiFi dataset
DNAstack collaboration is expected to create the largest, most Clinical diverse federated HiFi dataset centered on rare disease genomics PacBio HiFi is expected to power the first global federated HiFi whole genome dataset - Members committed to connect >10,000 HiFi whole genome sequences ~ 30 clini
Slide 6: Basecamp Research's Trillion Gene Atlas marks the largest collaboration in PacBio's history
Basecamp Research's Trillion Gene Atlas marks the largest collaboration in PacBio's history ✓ Potential to enable a new class of biological foundation model ✓ Aim to expand known genetic diversity by Trillion Gene Atlas as much as 100-fold ✓ Sequence up to 100+ million species ~100,000 samples to be
Slide 7: Q1 2026 revenue breakdown
Q1 2026 revenue breakdown Product & Service Regional Asia Pacific Consumables $9.7M $21.8M (16%) Y/Y Instruments 9% Y/Y Americas $9.7M (12%) Y/Y $37.2M $16.7M $37.2M 2% Y/Y EMEA $10.8M Service + Other 17% Y/Y $5.6M (7%) Y/Y 7
Slide 8: Q1 2026 non-GAAP financial highlights
Q1 2026 non-GAAP financial highlights Non-GAAP1 Measures Q1 2026 Q1 2025 Non-GAAP Gross Profit $13.8M $15.0M Non-GAAP Gross Margin 37% 40% Non-GAAP Operating Expenses $49.9M $61.7M Non-GAAP Net Loss ($35.9M) ($44.4M) Non-GAAP Basic Net Loss Per Share ($0.12) ($0.15) Mar 31, 2026 Dec 31, 2025 Cash &
Slide 9: Updating 2026 guidance
Updating 2026 guidance Revenue $165M - $175M 3% - 9% y/y growth Non-GAAP Gross Margin Non-GAAP Operating Expenses 41% - 44% $220M - $225M vs. 40% in 2025 vs. $230M in 2025 9
Slide 10: 2026 focus areas
2026 focus areas Dramatically improve the economics of HiFi through SPRQ-Nx with multi-use SMRT cells Accelerate clinical adoption across rare disease, oncology, and carrier screening Enable discovery through large-scale studies with HiFi’s rich data and high-throughput capabilities Empower next-gen
Slide 11: Our mission
Our mission Enabling the promise of genomics to better human health Creating the world’s most advanced sequencing technologies 11
Slide 12: Appendix
Appendix PacBi@ 12
Slide 13: Unaudited Condensed Consolidated Statements of Operations
Pacific Biosciences of California, Inc. ‘Unaudited Condensed Consolidated Statements of Operations “Three Monthtndad Maehs1,—Devemberst, Macht, (Grthousend, except pershare amounts) ‘aaa ‘mes ‘one Revenue Product revenue 3 seoss $3118 ‘Senice ard other reverue 6.040 Totalrevenue 37158 Cost of Revenu
Slide 14: Condensed Consolidated Balance Sheets
PacBi@ (in thousands) 2026 Accounts receivable, net i i Prepaid expenses and other current assets: 13,164 10,793 Operating lease right-of-use assets, net & & & 3 Intangible assets, net 14,104 15,124 : i 5 i : i i atl i a gee ese
Slide 15: GAAP to non-GAAP reconciliation
PacBi@ (in tousands, except per share amounts) 2006 2025, [Change in fair value of contingent consideration ' Amortization of acquired intangible assets 1016 1016 7128 i { g Non-GAAP net loss S(35945)§ (37.579) GAAP basic netloss per share 3 8 3 3 sas i ih i i | t i i i i : i i i 4 ° * 8 ° 8 ° GAAP
Slide 16: www.pacb.com
www.pacb.com Research use only. Not for use in diagnostic procedures. © 2024 Pacific Biosciences of California, Inc. (“PacBio”). All rights reserved. Information in this document is subject to change without notice. PacBio assumes no responsibility for any errors or omissions in this document. Certa
Pacific Biosciences of California — Q1 2026 Earnings Presentation on 6ix